Skip to main content
GWGovwatch
CongressBillsCommitteesPresidentMoneyPulseMisconductElectionsMap
Donate

Weekly accountability digest

One email a week with new votes, moving bills, and misconduct updates. No spam.

GW

Govwatch. Public data about Congress, in one place, in plain English.

Built with public data. Not affiliated with the U.S. government.

Explore

  • Officials
  • Legislation
  • Committees
  • Congress Pulse
  • Trending Topics
  • Bipartisan Leaderboard
  • Weekly Digest
  • Misconduct
  • Predictions

Learn

  • How Congress Works
  • How a Bill Becomes Law
  • Campaign Finance 101
  • Glossary

Tools

  • My Representatives
  • Compare Members
  • Bill Watchlist
  • Search
  • District Map
  • Follow the Money
  • Watch Live

Site

  • About
  • Contact
  • Corrections
  • Privacy Policy
  • Terms of Service

Data Sources

Congress.gov API v3
Bills, members, votesGovInfo API
Floor speeches, reports, bill textFederal Election Commission (FEC)
Campaign financeVoteView (UCLA)
Ideology scores (DW-NOMINATE)GovTrack.us
Misconduct data (CC0)U.S. Census Bureau
District demographics

Data Last Updated

Bills & Votes: 5 hours ago
Support This Project

This site is free. Donations help cover hosting, API fees, and keeping the data fresh.

All data is sourced from official government APIs and public records. This site is for informational purposes only.

© 2026 Govwatch

S1717Referred to Committee

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-05-12
Introduced
5
Cosponsors
S
ⓘ
Type

Sponsor

Todd Young
Todd Young
Republican · IN · Senator
Votes with party: 74.6% (850 recorded votes)

Full profile: /officials/Y000064

Source: Congress.gov · FEC

Cosponsors (5)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

5 cosponsors on record at Congress.gov. The named list is syncing into Govwatch and will appear here shortly — view on Congress.gov in the meantime.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Read twice and referred to the Committee on Finance.

2025-05-12

Source: Congress.gov

Committee Activity

Previously

  • Senate Committee on FinanceReferred To · 2025-05-12

Plain-English Summary

The legislation would allow patients faster access to certain new drugs and medical devices that show promise in treating serious or life-threatening conditions, even before they complete all standard FDA approval testing. This could benefit patients with diseases like cancer or rare conditions who have limited treatment options, though it may involve some additional risk since these products haven't undergone the full approval process. The changes would primarily affect pharmaceutical and medical device companies, patients, and the FDA's approval procedures.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health
Full bill text is not yet cached locally.
Open text viewRead on Congress.gov

Related legislation

Bills by the same sponsor or covering overlapping subjects.

  • S4943Outcomes-Based Financing (OBF) for Students Act
    Referred to Committee · 2026-06-24
  • S4770Web of Biological Data Act of 2026
    Referred to Committee · 2026-06-11
  • S4751End Tuberculosis Now Act of 2026
    Referred to Committee · 2026-06-11
  • S4653A bill to amend the Internal Revenue Code of 1986 to allow a deduction for loan interest payments made with respect to certain vehicles.
    Referred to Committee · 2026-06-02